-
Flonase continues market strength
GSK Consumer Healthcare’s Flonase allergy remedy was the single greatest generator of incremental dollars for the 52 weeks ended May 15 across total U.S. multi-outlets, according to IRI data, with $345.2 million in sales on 209.9% growth. The question headed into its second year on OTC shelves is can it maintain its momentum now that private-label competition for Flonase has reached store shelves.
-
Dry eye drives sales growth
Sales across the overall eye care and contact lens care categories generated $1.8 billion across total U.S. multi-outlets for the period ended May 15, representing growth of 2.4%. And dry eye continues to be a significant driver behind that growth, whether those dry eyes are caused by looking at a computer screen or smartphone all day or if there’s an underlying medical condition.